California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

China, India and the US will have the world’s largest populations of adults living with overweight and obesity by 2050, ...

A fuller picture of protein S deficiency emerged with large-scale research showing the immense thrombotic risks faced by ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

Anthropic on Monday closed its latest funding round at a $61.5 billion post-money valuation, the company confirmed to CNBC.

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

A medical device company has secured investment from the owner of the developer of Ozempic and a private equity firm, to ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...

Technology and Consumer Discretionary are the only two sectors down in the first two months of this year, among the 11 market ...